Clinical outcomes of TP53 mutations in cancers

Cold Spring Harbor Perspectives in Medicine

Volumn 6, Issue 9, 2016, Pages

  Robles, Ana I ^a   Jen, Jin ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

ACUTE MYELOBLASTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ARTICLE; BLADDER CARCINOMA; BLOOD; BREAST INVASIVE CARCINOMA; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOSARCOMA; CLEAR CELL CARCINOMA; CLINICAL OUTCOME; CLONE; COLORECTAL CARCINOMA; CUTANEOUS MELANOMA; CYSTADENOCARCINOMA; ESOPHAGUS CARCINOMA; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOMICS; GERMLINE MUTATION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; INVASIVE CARCINOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; NEOPLASM; OVARIAN CYSTADENOCARCINOMA; OVARY CARCINOMA; PANCREAS ADENOCARCINOMA; PROSTATE ADENOCARCINOMA; SOMATIC MUTATION; SQUAMOUS CELL LUNG CARCINOMA; STOMACH ADENOCARCINOMA; THYROID CARCINOMA; TUMOR BIOPSY; UTERINE CARCINOSARCOMA; UTERINE CERVIX CARCINOMA; UTERUS CARCINOMA; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; PATHOLOGY; TUMOR RECURRENCE;

DNA MUTATIONAL ANALYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84986222631     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a026294     Document Type: Article

References (137)

1. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. 2013. Signatures of mutational processes in human cancer. Nature 500: 415-421.
2. Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. 2014. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis 35: 586-596.
3. Bader AG. 2012. miR-34—A microRNA replacement therapy is headed to the clinic. Front Genet 3: 120.
4. Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. 2013. Metabolic regulation by p53 family members. Cell Metab 18: 617-633.
5. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al. 2014. Detection of circulating tumor DNA in earlyand late-stage human malignancies. Sci Transl Med 6: 224ra24.
6. Bisio A, Ciribilli Y, Fronza G, Inga A, Monti P. 2014. TP53 mutants in the tower of babel of cancer progression. Hum Mutat 35: 689-701.
7. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, et al. 2007. p53-mediated activation of miRNA34 candidate tumorsuppressor genes. Curr Biol 17: 1298-1307.
8. Bourdon JC. 2007. p53 and its isoforms in cancer. Br J Cancer 97: 277-282.
9. Bourdon JC, Khoury MP, Diot A, Baker L, Fernandes K, Aoubala M, Quinlan P, Purdie CA, Jordan LB, Prats AC, et al. 2011. p53 mutant breast cancer patients expressing p53g have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res 13: R7.
10. Bousquet G, Bouchtaoui ME, Leboeuf C, Battistella M, Varna M, Ferreira I, Plassa LF, Hamdan D, Bertheau P, Feugeas JP, et al. 2015. Tracking sub-clonal TP53 mutated tumor cells in human metastatic renal cell carcinoma. Oncotarget 5: 19279-19289.
11. Brachova P, Thiel KW, Leslie KK. 2013. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci 14: 19257-19275.
12. Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK. 2015. TP53 oncomorphic mutations predict resistance to platinum and taxane-based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol 46: 607-618.
13. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. 1991.A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci 88: 10124-10128.
14. Bressac B, Kew M, Wands J, Ozturk M. 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350: 429-431.
15. Brosh R, Rotter V. 2009. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer 9: 701-713.
16. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338-345.
17. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. 2012. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-404.
18. Chak BP, Chan ES, Tong JH, Leung AW, Cheng FW, Lam GK, Shing MM, Li CK, To KF. 2015. Germline TP53 mutations is common in patients with two early-onset primary malignancies. Clin Genet 87: 499-501.
19. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
20. Chang VY, Federman N, Martinez-Agosto J, Tatishchev SF, Nelson SF. 2013. Whole exome sequencing of pediatric gastric adenocarcinoma reveals an atypical presentation of Li-Fraumeni syndrome. Pediatr Blood Cancer 60: 570-574.
21. Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, et al. 2012. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci 109: 8241-8246.
22. Churi CR, Shroff R, Wang Y, Rashid A, Kang HC, Weatherly J, Zuo M, Zinner R, Hong D, Meric-Bernstam F, et al. 2014. Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS ONE 9: e115383.
23. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG. 2009. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138: 1083-1095.
24. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, et al. 2013. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58: 1693-1702.
25. Collins FS, Varmus H. 2015. A new initiative on precision medicine. N Engl J Med 372: 793-795.
26. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. 2007. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 67: 8433-8438.
27. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, et al. 2013. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368: 1199-1209.
28. Dodbiba L, Teichman J, Fleet A, Thai H, Starmans MH, Navab R, Chen Z, Girgis H, Eng L, Espin-Garcia O, et al. 2015. Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PLoS ONE 10: e0121872.
29. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. 1992. Definition of a consensus binding site for p53. Nat Genet 1: 45-49.
30. Fernandez SV, Bingham C, Fittipaldi P, Austin L, Palazzo J, Palmer G, Alpaugh K, Cristofanilli M. 2014. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients. Breast Cancer Res 16: 445.
31. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al. 2015. COSMIC: Exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res 43: D805-811.
32. Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, Dawson SJ, Piskorz AM, Jimenez-Linan M, Bentley D, et al. 2012. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4: 136-168.
33. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P, et al. 2013. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31: 1023-1031.
34. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. 2012.Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258.
35. Gonzalez KD, Buzin CH, Noltner KA, Gu D, Li W, Malkin D, Sommer SS. 2009. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 46: 689-693.
36. Govindan R, Weber J. 2014. TP53 mutations and lung cancer: Not all mutations are created equal. Clin Cancer Res 20: 4419-4421.
37. Guha T, Malkin D. 2016. Inherited TP53 mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a026187.
38. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, et al. 2015. Monitoring gastric cancer progression with circulating tumour DNA. Br J Cancer 112: 352-356.
39. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
40. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, et al. 2007. A microRNA component of the p53 tumour suppressor network. Nature 447: 1130-1134.
41. Hermeking H. 2007. p53 enters the microRNAworld. Cancer Cell 12: 414-418.
42. Hofstetter G, Berger A, Berger R, Zoric A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, et al. 2012. The N-terminally truncated p53 isoform D40p53 influences prognosis in mucinous ovarian cancer. Int J Gynecol Cancer 22: 372-379.
43. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253: 49-53.
44. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, et al. 2013. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45: 242-252.
45. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, Nakagawa M, Okita K, Yamanaka S. 2009. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.
46. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF Jr, Rice JM. 1995. Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 55: 2665-2672.
47. Horikawa I, Fujita K, Jenkins LM, Hiyoshi Y, Mondal AM, Vojtesek B, Lane DP, Appella E, Harris CC. 2014. Autophagic degradation of the inhibitory p53 isoform D133p53a as a regulatory mechanism for p53-mediated senescence. Nat Commun 5: 4706.
48. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350: 427-428.
49. Humpton TJ, Vousden KH. 2016. Regulation of cellular metabolism and hypoxia by p53. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a026146.
50. Hussain SP, Harris CC. 1999. p53 mutation spectrum and load: The generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 428: 23-32.
51. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, et al. 2000a. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: A cancer-prone chronic inflammatory disease. Cancer Res 60: 3333-3337.
52. Hussain SP, Raja K, Amstad PA, Sawyer M, Trudel LJ, Wogan GN, Hofseth LJ, Shields PG, Billiar TR, Trautwein C, et al. 2000b. Increased p53 mutation load in nontumorous human liver of Wilson disease and hemochromatosis: Oxyradical overload diseases. Proc Natl Acad Sci 97: 12770-12775.
53. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, et al. 2001. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 61: 6350-6355.
54. Jelinic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, Gao J, Schultz N, Gonen M, Soslow RA, et al. 2014. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet 46: 424-426.
55. Joerger AC, Ang HC, Fersht AR. 2006. Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci 103: 15056-15061.
56. Kamihara J, Rana HQ, Garber JE. 2014. Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Hum Mutat 35: 654-662.
57. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339.
58. Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C. 2003. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci 100: 8424-8429.
59. Kawamura T, Suzuki J, Wang YV, Menendez S, Morera LB, Raya A, Wahl GM, Izpisua Belmonte JC. 2009. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460: 1140-1144.
60. Kelleher FC, Solomon B, McArthur GA. 2012. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med 2: 35-49.
61. Khoo KH, Verma CS, Lane DP. 2014. Drugging the p53 pathway: Understanding the route to clinical efficacy. Nat Rev Drug Discov 13: 217-236.
62. Kulasekararaj AG, Smith AE, Mian SA, Mohamedali AM, Krishnamurthy P, Lea NC, Gaken J, Pennaneach C, Ireland R, Czepulkowski B, et al. 2013. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol 160: 660-672.
63. Lamolle G, Marin M, Alvarez-Valin F. 2006. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res 600: 102-112.
64. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, et al. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714-726.
65. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, et al. 2013. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499: 214-218.
66. Lee DF, Su J, Kim HS, Chang B, Papatsenko D, Zhao R, Yuan Y, Gingold J, Xia W, Darr H, et al. 2015.Modeling familial cancer with induced pluripotent stem cells. Cell 161: 240-254.
67. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A, et al. 2012. Targeting p53 in vivo: A first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30: 3633-3639.
68. Li FP, Fraumeni JF Jr. 1969. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 71: 747-752.
69. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362.
70. Li M, He Y, Feng X, Huang J. 2012. Genome-wide studies of the transcriptional regulation by p53. Biochim Biophys Acta 1819: 684-687.
71. Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ, Leemans CR, Braakhuis BJ. 2011. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res 17: 3733-3741.
72. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, et al. 2009. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4: 37-48.
73. Lu X, Liu DP, Xu Y. 2013. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 32: 2900-2906.
74. Lu C, Zhang J, Nagahawatte P, Easton J, Lee S, Liu Z, Ding L, Wyczalkowski MA, Valentine M, Navid F, et al. 2015. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol 135: 816-823.
75. Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. 2014. TP53 mutation analysis in clinical practice: Lessons from chronic lymphocytic leukemia. Hum Mutat 35: 663-671.
76. Malcikova J, Stano-Kozubik K, Tichy B, Kantorova B, Pavlova S, Tom N, Radova L, Smardova J, Pardy F, Doubek M, et al. 2015. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 29: 877-885.
77. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, et al. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238.
78. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, Diot A, Fernandes K, Tauro S, Bourdon JC. 2010. D160p53 is a novel N-terminal p53 isoform encoded by D133p53 transcript. FEBS Lett 584: 4463-4468.
79. Marion RM, Strati K, Li H, Murga M, Blanco R, Ortega S, Fernandez-Capetillo O, Serrano M, Blasco MA. 2009. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460: 1149-1153.
80. McCuaig JM, Armel SR, Novokmet A, Ginsburg OM, Demsky R, Narod SA, Malkin D. 2012. Routine TP53 testing for breast cancer under age 30: Ready for prime time? Fam Cancer 11: 607-613.
81. McNeil C. 2015. NCI-MATCH launch highlights new trial design in precision-medicine era. J Natl Cancer Inst 107: djv193.
82. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J. 2006. p53 suppresses the self-renewal of adult neural stem cells. Development 133: 363-369.
83. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, et al. 2015. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst 107: djv098.
84. Mirabello L, Yeager M, Mai PL, Gastier-Foster JM, Gorlick R, Khanna C, Patino-Garcia A, Sierrasesumaga L, Lecanda F, Andrulis IL, et al. 2015. Germline TP53 variants and susceptibility to osteosarcoma. J Natl Cancer Inst 107: djv101.
85. Mizuno H, Spike BT, Wahl GM, Levine AJ. 2010. Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures. Proc Natl Acad Sci 107: 22745-22750.
86. Molina-Vila MA, Bertran-Alamillo J, Gasco A, Mayo-delas-Casas C, Sanchez-Ronco M, Pujantell-Pastor L, Bonanno L, Favaretto AG, Cardona AF, Vergnenegre A, et al. 2014. Nondisruptive p53 mutations are associated with shorter survival in patients with advanced non-small cell lung cancer. Clin Cancer Res 20: 4647-4659.
87. Moreira AL, Won HH, McMillan R, Huang J, Riely GJ, Ladanyi M, Berger MF. 2015. Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis. J Thorac Oncol 10: 373-380.
88. Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B, Wu L, Truong S, Fernandes A, Grollman AP. 2011. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer 129: 1532-1536.
89. National Research Council. 2011. Toward precision medicine: Building a knowledge network for biomedical research and a new taxonomy of disease. National Academies Press, Washington, DC.
90. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al. 1989. Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708.
91. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, et al. 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167.
92. Olivier M, Hollstein M, Hainaut P. 2010. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008.
93. Oren M, Rotter V. 2010. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107.
94. Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, Jeon SS, Lee HM, Choi HY, Lee KS. 2013. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue. Cancer Sci 104: 631-638.
95. Parkin B, Ouillette P, Yildiz M, Saiya-Cork K, Shedden K, Malek SN. 2015. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia. Clin Cancer Res 21: 2045-2056.
96. Parry M, Rose-Zerilli MJ, Ljungstrom V, Gibson J, Wang J, Walewska R, Parker H, Parker AE, Davis Z, Gardiner A, et al. 2015. Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing. Clin Cancer Res 21: 4174-4183.
97. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al. 2007. TP53 mutations and survival in squamouscell carcinoma of the head and neck. N Engl J Med 357: 2552-2561.
98. Poon SL, Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, et al. 2013. Genomewide mutational signatures of aristolochic acid and its application as a screening tool. SciTranslMed 5: 197ra101.
99. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
100. Rivlin N, Koifman G, Rotter V. 2015. p53 orchestrates between normal differentiation and cancer. Semin Cancer Biol 32: 10-17.
101. Robles AI, Harris CC. 2010. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2: a001016.
102. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R, Rasi S, Monti S, Deambrogi C, De Paoli L, et al. 2014. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood 123: 2139-2147.
103. Rothe F, Laes JF, Lambrechts D, Smeets D, Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C, et al. 2014. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. Ann Oncol 25: 1959-1965.
104. Rucker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, Habdank M, Kugler CM, Holzmann K, Gaidzik VI, et al. 2012. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood 119: 2114-2121.
105. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci 74: 5463-5467.
106. Sarig R, Rivlin N, Brosh R, Bornstein C, Kamer I, Ezra O, Molchadsky A, Goldfinger N, Brenner O, Rotter V. 2010. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 207: 2127-2140.
107. Schetter AJ, Harris CC. 2012. Tumor suppressor p53 (TP53) at the crossroads of the exposome and the cancer genome. Proc Natl Acad Sci 109: 7955-7956.
108. Schulze K, Imbeaud S, Letouze E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, et al. 2015. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47: 505-511.
109. Schwede M, Spentzos D, Bentink S, Hofmann O, Haibe-Kains B, Harrington D, Quackenbush J, Culhane AC. 2013. Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosis. PLoS ONE 8: e57799.
110. Schwitalla S, Ziegler PK, Horst D, Becker V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R, Slotta-Huspenina J, et al. 2013. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogeninduced colorectal tumors. Cancer Cell 23: 93-106.
111. Senturk S, Yao Z, Camiolo M, Stiles B, Rathod T, Walsh AM, Nemajerova A, Lazzara MJ, Altorki NK, Krainer A, et al. 2014. p53C is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. Proc Natl Acad Sci 111: E3287-E3296.
112. Shimizu T, Marusawa H, Matsumoto Y, Inuzuka T, Ikeda A, Fujii Y, Minamiguchi S, Miyamoto S, Kou T, Sakai Y, et al. 2014. Accumulation of somatic mutations in TP53 in gastric epitheliumwith Helicobacter pylori infection. Gastroenterology 147: 407-417 e403.
113. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. 2012. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiationinduced senescence. Clin Cancer Res 18: 290-300.
114. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. 1990. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747-749.
115. Stengel A, Schnittger S, Weissmann S, Kuznia S, Kern W, Kohlmann A, Haferlach T, Haferlach C. 2014. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood 124: 251-258.
116. Stewart EL, Mascaux C, Pham NA, Sakashita S, Sykes J, Kim L, Yanagawa N, Allo G, Ishizawa K, Wang D, et al. 2015. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol 33: 2472-2480.
117. Streppel MM, Lata S, DelaBastide M, Montgomery EA, Wang JS, Canto MI, Macgregor-Das AM, Pai S, Morsink FH, Offerhaus GJ, et al. 2014. Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumorsuppressor gene in Barrett’s esophagus. Oncogene 33: 347-357.
118. Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT. 2003. Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10: 477-484.
119. Supek F, Minana B, Valcarcel J, Gabaldon T, Lehner B. 2014. Synonymous mutations frequently act as driver mutations in human cancers. Cell 156: 1324-1335.
120. Suzuki H, Takahashi T, Kuroishi T, Suyama M, Ariyoshi Y, Takahashi T, Ueda R. 1992. p53 mutations in non-small cell lung cancer in Japan: Association between mutations and smoking. Cancer Res 52: 734-736.
121. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H. 2007. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 6: 1586-1593.
122. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. 2007. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci 104: 15472-15477.
123. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. 2012. Patientderived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 9: 338-350.
124. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, et al. 2014. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 4: 1342-1353.
125. Tsongalis GJ, Peterson JD, de Abreu FB, Tunkey CD, Gallagher TL, Strausbaugh LD, Wells WA, Amos CI. 2014. Routine use of the Ion Torrent AmpliSeq Cancer Hotspot Panel for identification of clinically actionable somatic mutations. Clin Chem Lab Med 52: 707-714.
126. Villani A, Tabori U, Schiffman J, Shlien A, Beyene J, Druker H, Novokmet A, Finlay J, Malkin D. 2011. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: A prospective observational study. Lancet Oncol 12: 559-567.
127. Villanueva A, Hoshida Y. 2011. Depicting the role of TP53 in hepatocellular carcinoma progression. J Hepatol 55: 724-725.
128. Walters DM, Stokes JB, Adair SJ, Stelow EB, Borgman CA, Lowrey BT, Xin W, Blais EM, Lee JK, Papin JA, et al. 2013. Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens. PLoS ONE 8: e77065.
129. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Dunning MJ, et al. 2014. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 46: 837-843.
130. Weinberg RA. 1991. Tumor suppressor genes. Science 254: 1138-1146.
131. Whibley C, Pharoah PD, Hollstein M. 2009. p53 polymorphisms: Cancer implications. Nat Rev Cancer 9: 95-107.
132. Wild CP. 2005. Complementing the genome with an “exposome”: The outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 14: 1847-1850.
133. Woo HG, Wang XW, Budhu A, Kim YH, Kwon SM, Tang ZY, Sun Z, Harris CC, Thorgeirsson SS. 2011. Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology 140: 1063-1070.
134. Yamada H, Shinmura K, Yamamura Y, Kurachi K, Nakamura T, Tsuneyoshi T, Yokota N, Maekawa M, Sugimura H. 2009. Identification and characterization of a novel germline p53 mutation in a patient with glioblastoma and colon cancer. Int J Cancer 125: 973-976.
135. Yurgelun MB, Masciari S, Joshi VA, Mercado RC, Lindor NM, Gallinger S, Hopper JL, Jenkins MA, Buchanan DD, Newcomb PA, et al. 2015. Germline TP53 mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry. JAMA Oncol 1: 212-214.
136. Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D, Buhler A, Edelmann J, Bergmann M, Hopfinger G, et al. 2010. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28: 4473-4479.
137. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ, et al. 2013. Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4: 2935.